ANTICALMODULIN DRUGS DUE TO THE NET EFFECTS CANNOT ANTAGONIZE DIBUTYRYL-CAMP-MEDIATED SUPPRESSION OF DE NOVO SYNTHESIZED LIPID SECRETION IN BOTH CULTURED MCARDLE CELLS AND RAT HEPATOCYTES

MEHDI RASOULI* AND RICHARD LEHNER**

From the Department of Pediatrics and Cell Biology, CIHR Group on Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, Canada. T6G 2S2.

ABSTRACT

The effects and interaction between cAMP-analogue dibutyryl-cAMP and calmodulin antagonists were investigated on de novo synthesis and secretion of lipids in cultures of hepatoma McArdle-RH7777 cells and normal rat hepatocytes. Dibutyryl-cAMP caused a significant decrease in the secretion of de novo synthesized triacyl[3H]glycerol in both cultures of McArdle cells and rat hepatocytes. The inhibitory effect of dibutyryl-cAMP was concentration-dependent and appeared at the lowest concentration examined, 5 µM. Dibutyryl-cAMP at a concentration of 50 µM suppressed secretion of triacylglycerol by approximately 38% (p<0.05) and secretion of phosphatidylcholine by 30% (p<0.05). Dibutyryl-cAMP did not affect the synthesis of triacylglycerol and phosphatidylcholine, except at the highest concentration tested, 500 µM, where both triacylglycerol and phosphatidylcholine synthesis were suppressed significantly.

Anticalmodulin W-7 also inhibited secretion of newly made triacylglycerol in a concentration-dependent manner in both cultures of McArdle cells and rat hepatocytes. W-7 at a concentration of 20 µM suppressed triacylglycerol secretion by about 37% (p<0.05), while the secretion of phosphatidylcholine and synthesis of triacylglycerol and phosphatidylcholine were not affected, unless at more than 20 µM concentration, at which both triacylglycerol and phosphatidylcholine synthesis were decreased significantly.

*Corresponding author. Assistant professor of clinical biochemistry at University of Sari and visitor scientist at University of Alberta. Current address: Department of Clinical Biochemistry, Medical Sciences University of Mazandaran, Sari, Iran. E-mail address: mehdi2rasouli@yahoo.com.

**Medical scientist at University of Alberta. Address: Department of Pediatrics and Cell Biology, University of Alberta, 328 Heritage Medical Research Centre, Edmonton, Alberta, Canada.
Inhibition of VLDL Secretion by cAMP and Calmodulin Antagonists

The inhibitory effect elicited by dibutyryl-cAMP (100 µM) was not abolished in the presence of calmodulin antagonists, W-7 (20 µM), trifluoperazine (20 µM) and chlorpromazine (20 µM). The simultaneous effects of dibutyryl-cAMP and either calmodulin antagonists were not additive or synergistic. None of the calmodulin antagonists affected the cellular content of de novo synthesized triacylglycerol and phosphatidylcholine significantly. Neither dibutyryl-cAMP nor any calmodulin antagonist or their combination did affect the overall rate of de novo synthesis of triacylglycerol and phosphatidylcholine. All calmodulin antagonists examined alone also had a net significant inhibitory effect on the secretion of newly made triacylglycerol. The results presented here suggest that calmodulin antagonists have net direct effects and hence could not overcome dibutyryl-cAMP-induced suppressive effects on the secretion of newly made triacylglycerol. The cell types, normal hepatocytes relative to hepatomas, did not influence the results.

Keywords: Calmodulin, Cyclic AMP, Hepatocyte, Phosphatidylcholine, McArdle cells, Triacylglycerol and VLDL.

INTRODUCTION

The intrahepatic metabolism of VLDL is subject to control by both cAMP and calcium/calmodulin signal transduction pathways. The secretion of VLDL has been reported to be suppressed not only by calcium-linked agents such as catecholamines, prostaglandins, and calcium antagonists, but also by agents acting via cyclic AMP (cAMP) pathway including glucagon. cAMP dependent protein kinase and cAMP derivatives. There are several interactions between these two transduction pathways that may lead to the regulation of apoB containing lipoproteins metabolism. There is some evidence that the effect of cAMP is mediated at least partially, via the Ca2+/calmodulin pathway. Stimulation of cAMP pathway raises levels of inositol 1,4,5 triphosphate (IP3) and mobilizes Ca2+ in rat and guinea-pig hepatocytes and bovine parotid acinar cells. The cAMP analogues and forskolin (an adenylyl cyclase activator) also raised cytosolic calcium in rat hepatocytes. Cyclic AMP also induces “capacitative calcium entry” in rat hepatocytes. It is reported that, calmodulin antagonist N-(6-aminohexyl)-5-chloro-1-naphtalene sulfonamide (W-7) abolished cAMP-mediated effect of calcitonin on VLDL secretion in rat hepatocytes. W-7 also antagonized ACTH or cAMP-induced cholesteryl esters hydrolysis and steroidogenesis in adrenocortical cells. However in order to examine the role of the Ca2+/calmodulin pathway on cAMP mediated events, it is required that the anticalmodulin drugs themselves do not exert any direct side effects. W-7 and anti-psychotic drugs such as phenothiazines trifluoperazine and chlorpromazine have been known to function as calmodulin antagonists. In the present investigation, the hypothesis that the effect of cAMP is mediated via Ca2+/calmodulin was examined in cultured rat hepatoma McArdle-RH7777 cells and primary rat hepatocytes. The results demonstrated that calmodulin antagonists have a net direct suppressive effect on the secretion of lipids in both cell types, and hence, they cannot overcome the effects of dibutyryl-cAMP.

MATERIAL AND METHODS

Materials

Dibutyryl-cAMP, BSA (essentially fatty acid-free), collagenase 330 U/mg and W-7 (N-(6-aminohexyl)-5-chloro-1-naphtalene sulfonamide), trifluoperazine and chlorpromazine were purchased from Sigma (St. Louis, MO). [1(3)-1H]glycerol (2.6 Ci/mmol) was obtained from Amersham Canada (Oakville, Ontario, Canada). Dulbecco’s modified Eagle’s medium (DMEM), sodium pyruvate, penicillin/streptomycin, and fetal bovine and horse sera were from Gibco BRL (Life Technologies Inc., Grand Island, NY). TLC plates were purchased from Mandel Ltd. (Canada). All other chemicals and solvents were of reagent or better quality and were obtained from local suppliers.

Growth of McArdle cells

Wild typed McArdle RH-7777 cells obtained from ATCC were cultured in 60 mm dishes with DMEM containing pyruvate, antibiotics, 10% (v/v) fetal bovine serum and 10% (v/v) horse serum. When the cells reached about 70% confluency, the medium was changed to serum-free DMEM experimental medium as described in the legends of figures. All cultures were maintained in
100 mm dishes (Corning) at 37°C in humidified air (90% saturation) containing 5% CO₂. The hepatocytes were prepared under sterile conditions from male Spargue-Dawley rats (150-200 g) by a two-step collagenase method. In brief, the liver was perfused in situ with Ca²⁺ free Hank's saline buffer containing EGTA (0.5 mM) for 1 min., followed by Hank's solution containing Ca²⁺ (2 mM) and collagenase (200 IU/ml) for 9 min. Isolated hepatocytes were suspended in DMEM containing 15% fetal calf serum and centrifuged two times at 50 g for 2 min. The final cell suspension was counted in the presence of 0.04% trypan blue. Exclusion of the dye was >90% in all preparations. Cells were plated in DMEM containing 15% calf serum in collagen-coated (87 µg/ml) 60 mm dishes for 6 h in an atmosphere of air/CO₂ (19:1). Afterwards, medium and non-adherent cells were discarded and adherent cells washed with 3×2 mL of fresh DMEM. Cells were incubated in 2 mL of DMEM containing oleate/BSA (0.3 mM/0.5%, v=5) and other drugs as described in the legends of figures. At the end of the incubation period, the cells were cooled to 4°C on ice and the medium was collected. The cells were washed with ice cooled phosphate-buffered saline (PBS) and removed from the dish as described previously. Cells and media were analyzed for assays of lipids and protein.

Lipid analysis
At the end of incubations, media were separated from the cells and cells were washed with ice-cold phosphate-buffered saline, harvested in the same buffer and dispersed by brief sonication. Cellular and media lipids were extracted according to Folch et al. in the presence of non-labeled lipid carrier. The lipids were applied to thin-layer chromatography plates and developed to 1/3 the height with chloroform/methanol/acetic acid/water (25:15:4:2 by vol.) to separate glycerophospholipids, followed by development in heptane/isopropanol ether/acetic acid (60:40:4 by vol.) to separate neutral lipids. The lipid spots were visualized by exposure to iodine, and bands corresponding to various lipid classes were scraped and the associated radioactivity was determined by scintillation counting.

Other methods
Protein concentration was determined by the method of Bradford by the Bio-Rad protein assay kit using BSA as a protein standard. Oleate/BSA complex was prepared as described previously. The final concentration of oleate/BSA was 0.3 mM/0.5% (molar ratio of oleate to BSA is v=5).

Statistical analysis
The significant differences between samples and corresponding control were accessed by t-student test. The results are presented as the means ± SEM of two inter-assays performed at least in three different cell preparations.

RESULTS
The effects of increasing concentration of dibutyryl-cAMP on de novo synthesis and secretion of lipids in cultured McArdle cells
It has been reported that the cAMP transduction pathway is attenuated in hepatoma cells relative to normal hepatocytes, hence concentration dependence of dibutyryl-cAMP was analyzed on de novo synthesis and secretion of lipids in cultured McArdle cells.

![Graph showing concentration-response curves for the effects of dibutyryl-cAMP on the secretion and de novo synthesis of lipids in cultured McArdle cells.](image)

Fig. 1. Concentration-response curves for the effects of dibutyryl-cAMP on the secretion and de novo synthesis of lipids in cultured McArdle cells. McArdle-RH7777 cells at 70% confluency incubated 2 h in 2 mL DMEM containing oleate/BSA (0.3 mM/0.5%) and [³H]glycerol (5 µCi/dish) in the absence (control) and presence of different concentrations of dibutyryl-cAMP (0, 5, 50, 500 µM) as described in Methods section. The data represent (A) secretion of de novo made TG and PC and (B) de novo synthesis of TG and PC. The results are presented as the means ± SEM of two interassays performed at least in three different cell preparations. All samples are compared to the respective control. * Indicate that the corresponding value is significantly different from its control at the p<0.05 confidence level. Error bars for several determinations are too small to be seen.
Table 1. Effects of dibutyryl-cAMP on de novo synthesis and secretion of lipids in the absence and presence of calmodulin antagonist W-7 in cultured McArdle cells. McArdle cells at 70% confluency pre-incubated 15 min in 4 mL serum free DMEM in the absence or presence of W-7 (20 μM) followed by incubating for 2 h in 2 mL fresh DMEM containing olate/BSA (0.3 mM/0.5%), [3H]glycerol (10μCi/dish), dibutyryl-cAMP (100 μM) and W-7 (20 μM) individually or together. At the end of incubation period, media and cells were collected and analyzed for lipids and protein determination as described in Methods. The results are presented as the means ± SEM of two interassays performed at least in three different cell preparations. All samples were compared to the respective control, whereas dibutyryl-cAMP and W-7 combined treated sample was compared to dibutyryl-cAMP treated one as control. The absolute values for the control are given in parentheses in the first row, as dpm×10⁻³/mg cell protein. a And b indicate that the corresponding value is significantly different from its respective control at the p<0.05 and p=0.06 confidence level respectively. NS, indicates not significant relative to dibutyryl-cAMP treatment.

<table>
<thead>
<tr>
<th>Addition(s)</th>
<th>Medium</th>
<th></th>
<th>Cells</th>
<th></th>
<th>Synthesized (medium + cell)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TG</td>
<td>PC</td>
<td></td>
<td>TG</td>
<td>PC</td>
</tr>
<tr>
<td>control</td>
<td>100±14.4</td>
<td>100±13.9</td>
<td>100±10.8</td>
<td>100±6.8</td>
<td>100±11.3</td>
</tr>
<tr>
<td></td>
<td>(804.2±115.6)</td>
<td>(70.6±5.7)</td>
<td>(2491±156.3)</td>
<td>(3152.3±125.6)</td>
<td>(3295.9±216.9)</td>
</tr>
<tr>
<td>Bt-cAMP(100μM)</td>
<td>60.6±0.8ᵃ</td>
<td>63.1±6.2ᵃ</td>
<td>94.6±15.4</td>
<td>103.4±3.6</td>
<td>85.4±2.6</td>
</tr>
<tr>
<td>W-7(20μM)</td>
<td>67.9±1.2ᵇ</td>
<td>77.7±1.4ᵇ</td>
<td>111.1±2.6</td>
<td>110.3±3.0</td>
<td>100.6±1.7</td>
</tr>
<tr>
<td>Bt-cAMP+ W-7</td>
<td>57.3±4.9ᵇ, NS</td>
<td>68.3±7.4ᵇ</td>
<td>94.5±15.4</td>
<td>89.2±8.8</td>
<td>85.5±12.5</td>
</tr>
</tbody>
</table>

Dibutyryl-cAMP suppressed secretion of de novo made TG in a concentration-dependent manner (Fig. 1A). The concentration of dibutyryl-cAMP required for significant inhibition of TG secretion was 50 μM. At this concentration, the suppression of TG secretion was approximately 38% (p<0.05). The secretion of PC was also decreased by 30% (p<0.05). Dibutyryl-cAMP had no significant effect on the cellular content of [3H]glycerol-labeled TG and PC, except at the highest concentration examined, 500 μM (data not shown). The overall rate of de novo synthesis of TG and PC was calculated from the sum of the labeled medium and cellular TG and PC when cells were cultured in the presence of exogenous [3H]glycerol (Fig. 1B). Dibutyryl-cAMP had no significant effect on de novo synthesis of TG and PC, except at the highest concentration used (500 μM), where both TG and PC synthesis were suppressed 26% (p<0.05) and 16% (p<0.004) respectively.

The effects of increasing concentration of W-7 on de novo synthesis and secretion of lipids in cultured McArdle cells

It has been reported that the calcium/calmodulin transduction pathway is more sensitive to stimulation in hepatoma cells compared to normal hepatocytes. Hence, concentration-dependence of the effect of W-7 was examined on de novo synthesis and secretion of lipids in cultured McArdle cells. W-7 suppressed secretion of newly made TG in a concentration-dependent way. W-7 at 20 μM inhibited secretion of TG by about 37% (p<0.05). W-7 had no significant effect on PC secretion unless at concentrations higher than 20 μM, where PC synthesis is inhibited significantly. W-7 had no significant effect on the cellular content of [3H]glycerol-labeled TG and PC (result not shown) and on de novo synthesis of TG and PC (Fig. 2B), except at more than 20 μM both TG and PC synthesis were suppressed by 20% (p<0.05) and 30% (p<0.01) respectively.

Effects of W-7 on dibutyryl-cAMP-induced suppression of the secretion of de novo synthesized lipids in cultured McArdle cells

In order to investigate the possible involvement of calcium/calmodulin in the secretion of lipids from McArdle cells, the effects of dibutyryl-cAMP and W-7 were examined individually or together (Table 1). The concentration of dibutyryl-cAMP (100 μM) μM were chosen since at these concentrations the agents did not have any significant effects on de novo synthesis of glycerolipids TG and PC. In addition, 100 μM concentration of dibutyryl-cAMP is near the concentration for half of the maximum effect (EC50). Dibutyryl-cAMP inhibited the secretion of de novo made TG by 39% (p<0.05) and also PC by 37% (p<0.06). Since...
W-7 itself caused a net decrease in TG secretion by 38% (p<0.05), it could not antagonize the inhibitory effect of dibutyryl-cAMP. The simultaneous effect of dibutyryl-cAMP and W-7 was not additive or synergistic. Neither dibutyryl-cAMP nor W-7 had any significant effect on de novo synthesis of TG and PC.

_Calmodulin antagonists did not reverse the inhibitory effect of dibutyryl-cAMP on the secretion of lipids in cultured primary rat hepatocytes_

In order to clarify further the inhibition of lipid secretion by calmodulin antagonists, primary rat hepatocytes which are a more physiological model for lipid metabolism were treated. As in the hepatoma cells, dibutyryl-cAMP at concentration of 100 μM inhibited secretion of TG 38% (p<0.05) from primary rat hepatocytes, while PC secretion did not change significantly (Fig. 3A). Dibutyryl-cAMP did not appear to have any significant effect on de novo synthesis of TG and PC. All calmodulin antagonists examined W-7 (20 μM), trifluoperazine (20 μM) and chlorpromazine (20 μM) could not overcome
Inhibition of VLDL Secretion by cAMP and Calmodulin Antagonists

The inhibitory effect of dibutyryl-cAMP and each of the calmodulin antagonists were tested, however, none of the calmodulin antagonists examined here had no significant effect on triacylglycerol and phosphatidylecholine synthesis at least at the concentration employed (Fig. 4A). Thus it seems that suppression of TG secretion at the concentration of calmodulin antagonists <20 μM is not related to the inhibition of glycerolipids TG and PC synthesis.

DISCUSSION

The data presented here revealed that, cAMP analogue dibutyryl-cAMP inhibits TG secretion in hepatoma McArdle cells at the same concentration observed for normal rat hepatocytes and perfused rat liver. It has been reported that, CAMP transduction pathway is modified in hepatoma cells. The low level of CAMP in hepatoma cell lines is related to less adenylate cyclase and more phosphodiesterase activity. However none is eligible to dibutyryl-cAMP, since it is not produced by adenylate cyclase and is not susceptible to hydrolysis by phosphodiesterase. Bjornsson et al. have shown that activation of CAMP pathway via protein kinase-A inhibits the secretion of apoB containing lipoproteins in a situation that TG and PC synthesis were unaffected. It has also been reported that, dibutyryl-cAMP at low concentration did not affect cholesterol biosynthesis. Hence, the inhibitory effect of CAMP at low concentration on TG secretion is not attributed to the inhibition of TG, PC and cholesterol synthesis. There is a dual reciprocal control over the esterification and oxidation of fatty acids. Inhibition of de novo synthesis of fatty acids accompanied by channeling of exogenous fatty acids and fatty acids released by lipolysis of endogenous TG stores to oxidative pathway would be a probable mechanism via which dibutyryl-cAMP diminished TG secretion.

Secretion of VLDL-associated components is down regulated by both signal transduction pathways; CAMP and calcium/calmodulin. It has been shown that both α-adrenoceptor agonist phenylephrine and β-adrenoceptor agonist isoproterenol suppress secretion of triacyglycerol in freshly prepared hepatocytes. The effects of glucagon and isoproterenol are also exerted via two signal transduction pathways. However by now, the partition and interaction between these two pathways on the regulation of VLDL secretion have not been determined. According to “dual signaling” hypothesis there is much inter- and intra-cross-talk between the two transduction pathways. At the present time, the mechanism(s) whereby cAMP evokes cytosolic calcium is not established accurately, however, it has been shown that CAMP via protein kinase-A (PKA) phosphorylates Gq, IP₃ receptor and calcium channels. On the basis of the several reports this idea arose that the
effects of cAMP, at least partially may be mediated via Ca\(^{2+}\)/calmodulin pathway. To investigate the interaction between cAMP and calcium/calmodulin pathways, it is required that calmodulin antagonists alone have no net direct effects. Our results have shown that anticalmodulins due to the net side effects cannot overcome the inhibitory effects elicited by cAMP-analogue on triacylglycerol secretion.

In the present study, anticalmodulins unexpectedly inhibited the secretion of de novo made TG in both cultured hepatoma McArdle cells and normal rat hepatocytes. This finding about the net effects of calmodulin antagonists is in agreement to some reports\(^{20,28-31}\) and opposite to others.\(^{2,16,18}\) W-7 at all concentrations examined here, suppressed the secretion of lipids, however different mechanism(s) are probably involved at various concentrations. At W-7 concentration equal or less than 20 \(\mu\)M the effect cannot be attributed to the rates of glycerolipids synthesis since TG and PC synthesis were unaffected (Fig. 2B). The first explanation for the net inhibitory effect of W-7 on the secretion of lipids in hepatoma McArdle cells may be related to the nature of the cells. It is reported that the pathways of calcium/calmodulin and cAMP have been modified in hepatoma cells relative to normal rat hepatocytes.\(^{24,25}\) In hepatoma cell lines, the calcium/calmodulin pathway is more, while the cAMP-signaling pathway is less sensitive to stimulation. Hence, we have done similar experiments on both cell lines to exclude the possibility of the response to anticalmodulins due to the modified nature of hepatoma cells.\(^{33}\) However, similar results were obtained on both cell lines. Therefore, the assumption that, the response of McArdle cells to calmodulin antagonists is related to the modified nature of hepatoma cells will be ruled out.

The effects of anticalmodulins may be related to inhibition of calmodulin.\(^{4}\) Calmodulin activity may be involved in assembly and secretion of apoB containing lipoproteins\(^{4}\) and they probably would antagonize calmodulin-mediated effects that lead to suppression of lipids secretion. Available knowledge about the role of Ca\(^{2+}\)/calmodulin in the regulation of hepatic VLDL metabolism is limited. Intraluminal calcium of ER is required for proper folding and translocation of nascent apoB through secretory pathway.\(^{36}\) Calcium mobilizing agents release Ca\(^{2+}\) from intracellular stores (predominantly ER) to cytosol. Depletion of intraluminal Ca\(^{2+}\)-stores prevents secretion of apoB associated components,\(^{4}\) at the same time the increment in the cytosolic Ca\(^{2+}\) leads to activation of the calcium/calmodulin pathway\(^{28}\) and also trigger the microtubule-dependent exocytosis.\(^{37}\) Increment of cytosolic calcium leads to activation of exocytosis in all cells except in hepatocytes that lead to inhibition of VLDL secretion.\(^{2}\)

Other mechanisms also may be involved.

Anticalmodulin drugs have side effects that are related to nonspecific binding to other calcium-binding proteins (enzymes, receptors) and different membranes (plasma and ER membranes).\(^{20}\) Calmodulin antagonists bind to hydrophobic domain at calmodulin; the selectivity of binding was abolished at 10 \(\mu\)M or greater concentration of antagonist, since antagonists bind to other calcium-binding proteins.\(^{29}\) Unfortunately, by now it has not been possible to choose the appropriate concentration specific for only anticalmodulin activity. Indeed, many actions of calmodulin antagonists on membrane structure and hormone receptors occur at much lower concentration than needed to block calmodulin.\(^{29}\) It has been reported that, W-7 at low concentrations that we used here, enters into cultured fibroblasts and HepG2 cells and via interaction with \(\Delta\) 24-reductase, an enzyme involved in cholesterol synthesis inhibited de novo synthesis of cholesterol.\(^{30}\) By extending this mechanism to liver cells, and also from the results presented elsewhere,\(^{29}\) it can be deduced that, W-7 at low concentration (1-20 \(\mu\)M) inhibits de novo synthesis of cholesterol. At concentrations of 50 \(\mu\)M or higher calmodulin antagonists interact with the surface of the ER and change it to more positive.\(^{31}\) This can regulate the subcellular partition of peripherally membrane-associated enzymes involved in glycerolipids biosynthesis, phosphatidate phosphohydrolase\(^{31}\) and CTP: phosphocholine cytidylyltransferase.\(^{32}\) This subsequently leads to the inhibition of TG and PC syntheses (Fig. 2B).

In conclusion, the inhibitory effects of cAMP on VLDL secretion were not reversed by anticalmodulins. In fact, calmodulin antagonists presented at concentrations that did not alter overall glycerolipid biosynthesis also inhibited TG and PC secretion from both rat hepatoma and primary rat hepatocyte cells.

ACKNOWLEDGEMENT

We wish to thank Suzanne Lingrell for preparations of primary rat hepatocyte cultures and Dr. David N. Brindley for discussions. This work was supported by the grants from the Heart & Stroke Foundation of Alberta, NWT & Nunavut and the Alberta Heritage Foundation for Medical Research. Dr. Lehner is Alberta Heritage Foundation for Medical Research Scholar.

REFERENCES

Inhibition of VLDL Secretion by cAMP and Calmodulin Antagonists


